Table 4 Clinical trials associated with AA and its metabolites in different diseases or conditions
From: Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Date of Registration (y/m) | Registration number | Drug | Diseases or conditions | Target | Phase |
|---|---|---|---|---|---|
AA and its metabolites in cancers | |||||
2014/11 | NCT02169271 | Aspirin | Lung cancer | COX-1/2 | 2 |
2007/3 | NCT00468910 | Aspirin | Colorectal cancer | COX-1/2 | 2 |
2007/4 | NCT00474903 | Aspirin | Esophageal cancer | COX-1/2 | 2 |
2001/12 | NCT00582660 | Celecoxib | Colorectal adenoma | COX-2 | 2 |
2005/5 | NCT00466505 | Celecoxib | Colorectal cancer | COX-2 | 2 |
2010/2 | NCT01041781 | Celecoxib | Lung cancer | COX-2 | 3 |
2001/11 | NCT00084409 | Iloprost | Lung cancer | PGI2 | 2 |
2010/4 | NCT01111591 | Celecoxib | Bile duct cancer, Pancreatic cancer | COX-2 | 4 |
2012/2 | NCT01532362 | Apricoxib | Non-small cell lung cancer | COX-2 | NA |
2017/3 2003/3 | NCT02950480 NCT00056004 | Zafirlukast Zileuton | Breast cancer Lung cancer | LTD4 inhibitor 5-LOX inhibitor | 2 2 |
2010/5 2014/1 | NCT01021215 NCT02047149 | Zileuton Zileuton | Tobacco use disorder Chronic myelogenous leukemia | 5-LOX inhibitor 5-LOX inhibitor | 1 1 |
2013/12 | NCT02012920 | Seviteronel | Castration-resistant prostate cancer | CYP17 inhibitor | 2 |
2015/3 | NCT02381080 | Ibrutinib | B-cell chronic lymphocytic leukemia | CYP3A inhibitor | 1 |
2014/4 | NCT02122770 | MLN4924 | Advanced solid tumors | CYP3A inhibitors | 1 |
AA and its metabolites in CVD | |||||
2004/6 | NCT00646906 | Aspirin | Myocardial infarction, arthritis | COX-1/2 | NA |
2009/11 | NCT00990314 | Beraprost | Pulmonary arterial hypertension | PGI2 derivative | 2 |
2010/8 | NCT01268553 | Treprostinil | Pulmonary arterial hypertension | DP1 and EP2 agonist | 4 |
2009/12 | NCT01106014 | Selexipag | Pulmonary arterial hypertension | IP receptor agonist | 3 |
2006/7 | NCT00379808 | Montelukast | Coronary heart disease | Cys-LT1-receptor antagonist | NA |
2006/7 | NCT00358826 | VIA-2291 | Coronary artery disease | 5-LOX inhibitor | 2 |
2006/7 | NCT00352417 | VIA-2291 | Atherosclerosis | 5-LOX inhibitor | 2 |
2009/9 | NCT00872599 | Fenofibrate | Hypertension | PPARα activator | 4 |
2018/5 | NCT03318783 | GSK2256294 | Subarachnoid hemorrhage | sEH Inhibitior | 1 |
2006/1 | NCT00283335 | Gemfibrozil | Coronary heart disease | CYP enzyme inhibitor and PPARα activator | 3 |
2005/4 2009/1 | NCT00108511 NCT00847899 | Gemfibrozil AR9281 | Hypertriglyceridemia Hypertension, impaired glucose tolerance | CYP enzyme inhibitor and PPARα activator sEH Inhibitior | 1 2 |
AA and metabolites in other diseases | |||||
2018/9 | NCT03699293 | Naproxen sodium | Arthritis | COX-1/2 | 4 |
2006/5 | NCT00746720 | Etoricoxib | Osteoarthritis | COX-2 | 2 |
2014/12 | NCT02198924 | Parecoxib and Celecoxib | Pain, inflammation | COX-2 | 4 |
2017/10 | NCT03163966 | CR6086 | Rheumatoid arthritis | EP4 Antagonist | 2 |
2002/4 | NCT00092105 | Montelukast | Asthma | Cys-LT1-receptor antagonist | 3 |
2006/6 | NCT00461032 | Montelukast | Asthma | Cys-LT1-receptor antagonist | 3 |
2010/6 | NCT01147744 | GSK2190915 | Asthma | FLAP inhibitor | 2 |
2008/7 | NCT00723021 | Zileuton | Asthma | 5-LOX inhibitor | 2 |
2020/5 | NCT03486223 | GSK2256294 | Diabetes mellitus, endocrine system diseases, obesity | sEH Inhibitior | 2 |
2009/1 | NCT00847899 | AR9281 | Hypertension impaired glucose tolerance | sEH Inhibitior | 2 |
2019/7 | NCT04075110 | Montelukast | Obesity; endocrine; T2DM | Cys-LT1-receptor antagonist | 1 |
2015/4 | NCT02291666 | CRCHUM-MT cocktail | T2DM | CYP450 | 4 |
